Capricor Therapeutics joined PPMD for a community webinar on October 7, 2026, to share details about new 24-month data from the HOPE-3 open-label extension (OLE) study of Deramiocel for the treatment of Duchenne muscular dystrophy. Along with additional analyses, this HOPE-3 OLE data was recently submitted to the FDA as part of the company’s recent major amendment to the Deramiocel Biologics License Application (BLA). Capricor provides an overview of the data recently presented at the World Muscle Society Annual Meeting, and answers questions from the community.